Skip to main content
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC — Investor Relations & Filings

Ticker · OCTHF ISIN · GB00BMVMRB86 LEI · 2138005SRWT4998BCE35 IL Manufacturing
Open in API
Filings indexed 176 across all filing types
Latest filing 2023-08-31 Annual Report (ESEF)
Country GB United Kingdom
Listing IL OCTHF

About OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

https://www.oxcantech.com/

Oxford Cannabinoid Technologies Holdings PLC was a biopharmaceutical company engaged in the research, development, and commercialization of cannabinoid-based prescription medicines. The company's primary focus was on the pain market, with the goal of developing non-addictive medications to reduce reliance on opioids. Its drug discovery programs targeted the endocannabinoid system (ECS) and included a portfolio of proprietary cannabinoid derivatives, in-licensed compounds, and new chemical entities. According to its website, the company ceased trading and entered administration in May 2025.

Recent filings

Filing Released Lang Actions
Annual Report for the period ended 30 April 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2023-08-31 English
Annual Report for the period ended 30 April 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2023' for the year ended 30 April 2023. It contains comprehensive sections including a Strategic Report, Governance Report, Financial Statements, and Auditor's Report. It is a full-length annual report, not an announcement or a summary, and meets the criteria for a 10-K equivalent filing. FY 2023
2023-08-31 English
2023 Final Results
Report Publication Announcement Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Oxford Cannabinoid Technologies Holdings plc. It serves as a summary of the company's final results for the year ended 30 April 2023, while explicitly stating that the full annual report and accounts will be posted to shareholders in due course. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2023
2023-08-31 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a formal announcement released via RNS (RNS Number: 9880J) from Oxford Cannabinoid Technologies Holdings plc. The title is "Notice of Results & Analyst and Investor Presentations." The text explicitly states the company "intends to announce results for the period ended 30 April 2023 on Thursday 31 August 2023" and details the schedule for an Analyst Briefing and an Investor Presentation. This document is not the results themselves (ER or IR), nor is it the full presentation (IP). It is an announcement about the upcoming publication of results and associated events. According to Rule 2, when a document is short and announces the publication of another report, it fits the definition of a Report Publication Announcement (RPA).
2023-08-22 English
First Dose Administered & Pain Specialist Adviser
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and is distributed via 'RNS, the news service of the London Stock Exchange,' which is explicitly mentioned as the Primary Information Provider in the UK. The content announces two key operational updates: the first dose administered in a Phase I clinical trial for a drug candidate (OCT461201) and the appointment of a new external advisor (Dr Farquhar-Smith). These are typical corporate announcements made through regulatory news services. Since the content is a specific operational update (clinical trial progress and advisory appointment) rather than a general notice about a report being published (RPA) or a mandatory periodic filing (10-K, IR), and it is clearly distributed via the RNS system, the most appropriate classification is RNS (Regulatory Filings), which serves as the general category for such announcements not covered by more specific codes like DIV, DIRS, or ER.
2023-07-27 English
Director/PDMR Share Purchases
Director's Dealing Classification · 99% confidence The document is an official announcement filed via RNS (RNS Number : 2585G) dated July 17, 2023. The primary content explicitly details share purchases by a Director/PDMR (Chief Executive Officer and General Counsel/Company Secretary). This directly matches the definition of 'Director's Dealing' (insider trades by executives). The specific filing category for this is 'DIRS'.
2023-07-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.